Rani Therapeutics RaniPill platform joins FDA Emerging Technology Program
RANI•Rani Therapeutics’ RaniPill Capsule platform was accepted into the FDA’s Emerging Technology Program under CDER, enabling early engagement on technical and regulatory issues related to its design and manufacturing.
1. FDA program acceptance
The FDA’s Emerging Technology Program will allow early engagement on technical and regulatory issues tied to the RaniPill platform’s product design and manufacturing. Interactions can cover broader platform use beyond individual drug products and support plans to automate manufacturing ahead of wider clinical use.
